{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T03:16:30Z","timestamp":1649042190833},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Klin Intensivmed Notfmed"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00063-021-00812-5","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T12:03:15Z","timestamp":1617796995000},"page":"358-359","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alkalose, Albumin, Ammoniak und die hepatische Enzephalopathie"],"prefix":"10.1007","volume":"116","author":[{"given":"A.-R.","family":"Kabbani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. L.","family":"Tergast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Maasoumy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"issue":"2","key":"812_CR1","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/hep.27210","volume":"60","author":"H Vilstrup","year":"2014","unstructured":"Vilstrup\u00a0H, Amodio\u00a0P, Bajaj\u00a0J, Cordoba\u00a0J, Ferenci\u00a0P, Mullen\u00a0KD et\u00a0al (2014) Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American association for the study of liver diseases and the European association for the study of the liver. Hepatology 60(2):715\u2013735","journal-title":"Hepatology"},{"issue":"2","key":"812_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1099\/00222615-13-2-177","volume":"13","author":"AJ Vince","year":"1980","unstructured":"Vince\u00a0AJ, Burridge\u00a0SM (1980) Ammonia production by intestinal bacteria: the effects of lactose, lactulose and glucose. J\u00a0Med Microbiol 13(2):177\u2013191","journal-title":"J Med Microbiol"},{"issue":"12","key":"812_CR3","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1136\/gut.15.12.999","volume":"15","author":"RL Bown","year":"1974","unstructured":"Bown\u00a0RL, Gibson\u00a0JA, Sladen\u00a0GE, Hicks\u00a0B, Dawson\u00a0AM (1974) Effects of lactulose and other laxatives on ileal and colonic pH as measured by a\u00a0radiotelemetry device. Gut 15(12):999\u20131004","journal-title":"Gut"},{"issue":"4","key":"812_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S1665-2681(19)31831-9","volume":"7","author":"C Kiafar","year":"2008","unstructured":"Kiafar\u00a0C, Gilani\u00a0N (2008) Hepatic hydrothorax: current concepts of pathophysiology and treatment options. Ann Hepatol 7(4):313\u2013320","journal-title":"Ann Hepatol"},{"issue":"1","key":"812_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1161\/01.CIR.22.1.154","volume":"22","author":"H Heinemann","year":"1960","unstructured":"Heinemann\u00a0H (1960) Respiration and circulation in patients with portal cirrhosis of the liver. Circulation 22(1):154\u2013159","journal-title":"Circulation"},{"issue":"1","key":"812_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/hep.510250110","volume":"25","author":"SJ Lustik","year":"1997","unstructured":"Lustik\u00a0SJ, Chhibber\u00a0AK, Kolano\u00a0JW, Hilmi\u00a0IA, Henson\u00a0LC, Morris\u00a0MC et\u00a0al (1997) The hyperventilation of cirrhosis: progesterone and estradiol effects. Hepatology 25(1):55\u201358","journal-title":"Hepatology"},{"issue":"1","key":"812_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/0002-9343(86)90187-7","volume":"81","author":"JJ McAuliffe","year":"1986","unstructured":"McAuliffe\u00a0JJ, Lind\u00a0LJ, Leith\u00a0DE, Fencl\u00a0V (1986) Hypoproteinemic alkalosis. Am J Med 81(1):86\u201390","journal-title":"Am J Med"},{"issue":"3","key":"812_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jhep.2006.03.011","volume":"45","author":"G Funk","year":"2006","unstructured":"Funk\u00a0G, Doberer\u00a0D, Fuhrmann\u00a0V, Holzinger\u00a0U, Kitzberger\u00a0R, Kneidinger\u00a0N et al (2006) The acidifying effect of lactate is neutralized by the alkalinizing effect of hypoalbuminemia in non-paracetamol-induced acute liver failure. J\u00a0Hepatol 45(3):387\u2013392","journal-title":"J Hepatol"},{"issue":"1","key":"812_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13613-018-0391-9","volume":"8","author":"A Drolz","year":"2018","unstructured":"Drolz\u00a0A, Horvatits\u00a0T, Roedl\u00a0K, Rutter\u00a0K, Brunner\u00a0R, Zauner\u00a0C et al (2018) Acid-base status and its clinical implications in critically ill patients with cirrhosis, acute-on-chronic liver failure and without liver disease. Ann Intensive Care 8(1):1\u201312","journal-title":"Ann Intensive Care"},{"issue":"5","key":"812_CR10","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/hep.510280508","volume":"28","author":"W Nolte","year":"1998","unstructured":"Nolte\u00a0W, Wiltfang\u00a0J, Schindler\u00a0C, M\u00fcnke\u00a0H, Unterberg\u00a0K, Zumhasch\u00a0U et\u00a0al (1998) Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology 28(5):1215\u20131225","journal-title":"Hepatology"},{"issue":"9119:1861","key":"812_CR11","first-page":"78807","volume":"351","author":"F Moroni","year":"1998","unstructured":"Moroni\u00a0F, Carpenedo\u00a0R, Venturini\u00a0I, Baraldi\u00a0M, Zeneroli\u00a0ML (1998) Oxindole in pathogenesis of hepatic encephalopathy. Lancet 351(9119:1861):78807\u201378803","journal-title":"Lancet"}],"container-title":["Medizinische Klinik - Intensivmedizin und Notfallmedizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-021-00812-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00063-021-00812-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-021-00812-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T08:08:26Z","timestamp":1620288506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00063-021-00812-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["812"],"URL":"https:\/\/doi.org\/10.1007\/s00063-021-00812-5","relation":{},"ISSN":["2193-6218","2193-6226"],"issn-type":[{"value":"2193-6218","type":"print"},{"value":"2193-6226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"7 April 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.-R.\u00a0Kabbani erkl\u00e4rt, dass er Verbindungen zu Merck\/MSD (Reisekostenerstattung) hat. T.L.\u00a0Tergast gibt an, dass kein Interessenkonflikt besteht. M.P.\u00a0Manns erkl\u00e4rt, dass er Verbindungen (Principal Investigator\/Studien\/Vortrags-und Beraterhonorare) zu AbbVie, Bristol Myers Squibb, CureVac, Enyo Pharma, Falk Pharma, Janssen, Merck\/MSD, Gilead Sciences, Medgenics, Novartis, Roche, PregLem, Gedeon Richter und Allergan hat; zudem werden Reisekosten von AbbVie, Bristol Myers Squibb, Janssen, Merck\/MSD, Falk Pharma, Gilead Sciences, Novartis und Roche erstattet. B.\u00a0Maasoumy hat Vortrags- und\/oder Beraterhonorare von AbbVie, Bristol-Myers Squibb, Janssen, Merck\/MSD, Abbott, Fujirebio, Roche; Studienunterst\u00fctzung von Abbott, Fujirebio und Roche wie auch Reisekostenerstattungen von Gilead Science, Bristol-Myers Squibb, AbbVie, Merck\/MSD und Janssen erhalten.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}